

Global Recombinant Human GM-CSF for Injection Market Growth 2023-2029

<https://marketpublishers.com/r/GC9A1E7871CEEN.html>

Date: December 2023

Pages: 88

Price: US\$ 3,660.00 (Single User License)

ID: GC9A1E7871CEEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

According to our LPI (LP Information) latest study, the global Recombinant Human GM-CSF for Injection market size was valued at US\$ 84 million in 2022. With growing demand in downstream market, the Recombinant Human GM-CSF for Injection is forecast to a readjusted size of US\$ 110.3 million by 2029 with a CAGR of 3.9% during review period.

The research report highlights the growth potential of the global Recombinant Human GM-CSF for Injection market. Recombinant Human GM-CSF for Injection are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Recombinant Human GM-CSF for Injection. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Recombinant Human GM-CSF for Injection market.

Recombinant Human GM-CSF for Injection is a biopharmaceutical product that plays a critical role in stimulating the growth and function of granulocytes and macrophages, key components of the immune system. It is used to treat various medical conditions, including neutropenia, leukemia, and as an adjunct therapy for certain cancer treatments. The market for this product is substantial, driven by the rising prevalence of diseases that compromise the immune system and the development of immunotherapies. Its future development is likely to involve expanded applications in immune-related therapies, further improving patient outcomes in the treatment of various disorders.

Recombinant Human GM-CSF for Injection is a crucial biopharmaceutical product widely used in the treatment of various diseases, particularly leukemia and malignant tumors. The market for this product is substantial and continuously expanding, driven by advancements in medical technology and therapeutic approaches. In the future, it is expected that this field will continue to evolve, with specific uses of recombinant human GM-CSF potentially extending to include the treatment of more cancer types, offering further growth opportunities in the biopharmaceutical industry.

Key Features:

The report on Recombinant Human GM-CSF for Injection market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size and growth of the Recombinant Human GM-CSF for Injection market. It may include historical data, market segmentation by Type (e.g., 75ug, 150ug), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Recombinant Human GM-CSF for Injection market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the Recombinant Human GM-CSF for Injection market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the Recombinant Human GM-CSF for Injection industry. This include advancements in Recombinant Human GM-CSF for Injection technology, Recombinant Human GM-CSF for Injection new entrants, Recombinant Human GM-CSF for Injection new investment, and other innovations that are shaping the future of Recombinant Human GM-CSF for Injection.

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Recombinant Human GM-CSF for

Injection market. It includes factors influencing customer ' purchasing decisions, preferences for Recombinant Human GM-CSF for Injection product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Recombinant Human GM-CSF for Injection market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Recombinant Human GM-CSF for Injection market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Recombinant Human GM-CSF for Injection market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Recombinant Human GM-CSF for Injection industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Recombinant Human GM-CSF for Injection market.

Market Segmentation:

Recombinant Human GM-CSF for Injection market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Segmentation by type

75ug

150ug

Segmentation by application

Hospital

Clinic

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Sanofi

Changchun GeneScience

Hainan Unipul Pharmaceutical

Harbin Pharmaceutical Group

Guangzhou Baiyunshan Baidi Biotechnology

Key Questions Addressed in this Report

What is the 10-year outlook for the global Recombinant Human GM-CSF for Injection

market?

What factors are driving Recombinant Human GM-CSF for Injection market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Recombinant Human GM-CSF for Injection market opportunities vary by end market size?

How does Recombinant Human GM-CSF for Injection break out type, application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Recombinant Human GM-CSF for Injection Annual Sales 2018-2029
- 2.1.2 World Current & Future Analysis for Recombinant Human GM-CSF for Injection by Geographic Region, 2018, 2022 & 2029
- 2.1.3 World Current & Future Analysis for Recombinant Human GM-CSF for Injection by Country/Region, 2018, 2022 & 2029

2.2 Recombinant Human GM-CSF for Injection Segment by Type

- 2.2.1 75ug
- 2.2.2 150ug

2.3 Recombinant Human GM-CSF for Injection Sales by Type

- 2.3.1 Global Recombinant Human GM-CSF for Injection Sales Market Share by Type (2018-2023)
- 2.3.2 Global Recombinant Human GM-CSF for Injection Revenue and Market Share by Type (2018-2023)
- 2.3.3 Global Recombinant Human GM-CSF for Injection Sale Price by Type (2018-2023)

2.4 Recombinant Human GM-CSF for Injection Segment by Application

- 2.4.1 Hospital
- 2.4.2 Clinic
- 2.4.3 Others

2.5 Recombinant Human GM-CSF for Injection Sales by Application

- 2.5.1 Global Recombinant Human GM-CSF for Injection Sale Market Share by Application (2018-2023)
- 2.5.2 Global Recombinant Human GM-CSF for Injection Revenue and Market Share

by Application (2018-2023)

2.5.3 Global Recombinant Human GM-CSF for Injection Sale Price by Application (2018-2023)

3 GLOBAL RECOMBINANT HUMAN GM-CSF FOR INJECTION BY COMPANY

3.1 Global Recombinant Human GM-CSF for Injection Breakdown Data by Company

3.1.1 Global Recombinant Human GM-CSF for Injection Annual Sales by Company (2018-2023)

3.1.2 Global Recombinant Human GM-CSF for Injection Sales Market Share by Company (2018-2023)

3.2 Global Recombinant Human GM-CSF for Injection Annual Revenue by Company (2018-2023)

3.2.1 Global Recombinant Human GM-CSF for Injection Revenue by Company (2018-2023)

3.2.2 Global Recombinant Human GM-CSF for Injection Revenue Market Share by Company (2018-2023)

3.3 Global Recombinant Human GM-CSF for Injection Sale Price by Company

3.4 Key Manufacturers Recombinant Human GM-CSF for Injection Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Recombinant Human GM-CSF for Injection Product Location Distribution

3.4.2 Players Recombinant Human GM-CSF for Injection Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR RECOMBINANT HUMAN GM-CSF FOR INJECTION BY GEOGRAPHIC REGION

4.1 World Historic Recombinant Human GM-CSF for Injection Market Size by Geographic Region (2018-2023)

4.1.1 Global Recombinant Human GM-CSF for Injection Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Recombinant Human GM-CSF for Injection Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Recombinant Human GM-CSF for Injection Market Size by

Country/Region (2018-2023)

4.2.1 Global Recombinant Human GM-CSF for Injection Annual Sales by Country/Region (2018-2023)

4.2.2 Global Recombinant Human GM-CSF for Injection Annual Revenue by Country/Region (2018-2023)

4.3 Americas Recombinant Human GM-CSF for Injection Sales Growth

4.4 APAC Recombinant Human GM-CSF for Injection Sales Growth

4.5 Europe Recombinant Human GM-CSF for Injection Sales Growth

4.6 Middle East & Africa Recombinant Human GM-CSF for Injection Sales Growth

5 AMERICAS

5.1 Americas Recombinant Human GM-CSF for Injection Sales by Country

5.1.1 Americas Recombinant Human GM-CSF for Injection Sales by Country (2018-2023)

5.1.2 Americas Recombinant Human GM-CSF for Injection Revenue by Country (2018-2023)

5.2 Americas Recombinant Human GM-CSF for Injection Sales by Type

5.3 Americas Recombinant Human GM-CSF for Injection Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Recombinant Human GM-CSF for Injection Sales by Region

6.1.1 APAC Recombinant Human GM-CSF for Injection Sales by Region (2018-2023)

6.1.2 APAC Recombinant Human GM-CSF for Injection Revenue by Region (2018-2023)

6.2 APAC Recombinant Human GM-CSF for Injection Sales by Type

6.3 APAC Recombinant Human GM-CSF for Injection Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Recombinant Human GM-CSF for Injection by Country

7.1.1 Europe Recombinant Human GM-CSF for Injection Sales by Country (2018-2023)

7.1.2 Europe Recombinant Human GM-CSF for Injection Revenue by Country (2018-2023)

7.2 Europe Recombinant Human GM-CSF for Injection Sales by Type

7.3 Europe Recombinant Human GM-CSF for Injection Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Recombinant Human GM-CSF for Injection by Country

8.1.1 Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Country (2018-2023)

8.1.2 Middle East & Africa Recombinant Human GM-CSF for Injection Revenue by Country (2018-2023)

8.2 Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Type

8.3 Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Recombinant Human GM-CSF for Injection

10.3 Manufacturing Process Analysis of Recombinant Human GM-CSF for Injection

10.4 Industry Chain Structure of Recombinant Human GM-CSF for Injection

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Recombinant Human GM-CSF for Injection Distributors

11.3 Recombinant Human GM-CSF for Injection Customer

12 WORLD FORECAST REVIEW FOR RECOMBINANT HUMAN GM-CSF FOR INJECTION BY GEOGRAPHIC REGION

12.1 Global Recombinant Human GM-CSF for Injection Market Size Forecast by Region

12.1.1 Global Recombinant Human GM-CSF for Injection Forecast by Region (2024-2029)

12.1.2 Global Recombinant Human GM-CSF for Injection Annual Revenue Forecast by Region (2024-2029)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Recombinant Human GM-CSF for Injection Forecast by Type

12.7 Global Recombinant Human GM-CSF for Injection Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Sanofi

13.1.1 Sanofi Company Information

13.1.2 Sanofi Recombinant Human GM-CSF for Injection Product Portfolios and Specifications

13.1.3 Sanofi Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2018-2023)

13.1.4 Sanofi Main Business Overview

- 13.1.5 Sanofi Latest Developments
- 13.2 Changchun GeneScience
 - 13.2.1 Changchun GeneScience Company Information
 - 13.2.2 Changchun GeneScience Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
 - 13.2.3 Changchun GeneScience Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.2.4 Changchun GeneScience Main Business Overview
 - 13.2.5 Changchun GeneScience Latest Developments
- 13.3 Hainan Unipul Pharmaceutical
 - 13.3.1 Hainan Unipul Pharmaceutical Company Information
 - 13.3.2 Hainan Unipul Pharmaceutical Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
 - 13.3.3 Hainan Unipul Pharmaceutical Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.3.4 Hainan Unipul Pharmaceutical Main Business Overview
 - 13.3.5 Hainan Unipul Pharmaceutical Latest Developments
- 13.4 Harbin Pharmaceutical Group
 - 13.4.1 Harbin Pharmaceutical Group Company Information
 - 13.4.2 Harbin Pharmaceutical Group Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
 - 13.4.3 Harbin Pharmaceutical Group Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.4.4 Harbin Pharmaceutical Group Main Business Overview
 - 13.4.5 Harbin Pharmaceutical Group Latest Developments
- 13.5 Guangzhou Baiyunshan Baidi Biotechnology
 - 13.5.1 Guangzhou Baiyunshan Baidi Biotechnology Company Information
 - 13.5.2 Guangzhou Baiyunshan Baidi Biotechnology Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
 - 13.5.3 Guangzhou Baiyunshan Baidi Biotechnology Recombinant Human GM-CSF for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.5.4 Guangzhou Baiyunshan Baidi Biotechnology Main Business Overview
 - 13.5.5 Guangzhou Baiyunshan Baidi Biotechnology Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Recombinant Human GM-CSF for Injection Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)
- Table 2. Recombinant Human GM-CSF for Injection Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)
- Table 3. Major Players of 75ug
- Table 4. Major Players of 150ug
- Table 5. Global Recombinant Human GM-CSF for Injection Sales by Type (2018-2023) & (K Units)
- Table 6. Global Recombinant Human GM-CSF for Injection Sales Market Share by Type (2018-2023)
- Table 7. Global Recombinant Human GM-CSF for Injection Revenue by Type (2018-2023) & (\$ million)
- Table 8. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Type (2018-2023)
- Table 9. Global Recombinant Human GM-CSF for Injection Sale Price by Type (2018-2023) & (US\$/Unit)
- Table 10. Global Recombinant Human GM-CSF for Injection Sales by Application (2018-2023) & (K Units)
- Table 11. Global Recombinant Human GM-CSF for Injection Sales Market Share by Application (2018-2023)
- Table 12. Global Recombinant Human GM-CSF for Injection Revenue by Application (2018-2023)
- Table 13. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Application (2018-2023)
- Table 14. Global Recombinant Human GM-CSF for Injection Sale Price by Application (2018-2023) & (US\$/Unit)
- Table 15. Global Recombinant Human GM-CSF for Injection Sales by Company (2018-2023) & (K Units)
- Table 16. Global Recombinant Human GM-CSF for Injection Sales Market Share by Company (2018-2023)
- Table 17. Global Recombinant Human GM-CSF for Injection Revenue by Company (2018-2023) (\$ Millions)
- Table 18. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Company (2018-2023)
- Table 19. Global Recombinant Human GM-CSF for Injection Sale Price by Company

(2018-2023) & (US\$/Unit)

Table 20. Key Manufacturers Recombinant Human GM-CSF for Injection Producing Area Distribution and Sales Area

Table 21. Players Recombinant Human GM-CSF for Injection Products Offered

Table 22. Recombinant Human GM-CSF for Injection Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 23. New Products and Potential Entrants

Table 24. Mergers & Acquisitions, Expansion

Table 25. Global Recombinant Human GM-CSF for Injection Sales by Geographic Region (2018-2023) & (K Units)

Table 26. Global Recombinant Human GM-CSF for Injection Sales Market Share Geographic Region (2018-2023)

Table 27. Global Recombinant Human GM-CSF for Injection Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 28. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Geographic Region (2018-2023)

Table 29. Global Recombinant Human GM-CSF for Injection Sales by Country/Region (2018-2023) & (K Units)

Table 30. Global Recombinant Human GM-CSF for Injection Sales Market Share by Country/Region (2018-2023)

Table 31. Global Recombinant Human GM-CSF for Injection Revenue by Country/Region (2018-2023) & (\$ millions)

Table 32. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Country/Region (2018-2023)

Table 33. Americas Recombinant Human GM-CSF for Injection Sales by Country (2018-2023) & (K Units)

Table 34. Americas Recombinant Human GM-CSF for Injection Sales Market Share by Country (2018-2023)

Table 35. Americas Recombinant Human GM-CSF for Injection Revenue by Country (2018-2023) & (\$ Millions)

Table 36. Americas Recombinant Human GM-CSF for Injection Revenue Market Share by Country (2018-2023)

Table 37. Americas Recombinant Human GM-CSF for Injection Sales by Type (2018-2023) & (K Units)

Table 38. Americas Recombinant Human GM-CSF for Injection Sales by Application (2018-2023) & (K Units)

Table 39. APAC Recombinant Human GM-CSF for Injection Sales by Region (2018-2023) & (K Units)

Table 40. APAC Recombinant Human GM-CSF for Injection Sales Market Share by

Region (2018-2023)

Table 41. APAC Recombinant Human GM-CSF for Injection Revenue by Region (2018-2023) & (\$ Millions)

Table 42. APAC Recombinant Human GM-CSF for Injection Revenue Market Share by Region (2018-2023)

Table 43. APAC Recombinant Human GM-CSF for Injection Sales by Type (2018-2023) & (K Units)

Table 44. APAC Recombinant Human GM-CSF for Injection Sales by Application (2018-2023) & (K Units)

Table 45. Europe Recombinant Human GM-CSF for Injection Sales by Country (2018-2023) & (K Units)

Table 46. Europe Recombinant Human GM-CSF for Injection Sales Market Share by Country (2018-2023)

Table 47. Europe Recombinant Human GM-CSF for Injection Revenue by Country (2018-2023) & (\$ Millions)

Table 48. Europe Recombinant Human GM-CSF for Injection Revenue Market Share by Country (2018-2023)

Table 49. Europe Recombinant Human GM-CSF for Injection Sales by Type (2018-2023) & (K Units)

Table 50. Europe Recombinant Human GM-CSF for Injection Sales by Application (2018-2023) & (K Units)

Table 51. Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Country (2018-2023) & (K Units)

Table 52. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Market Share by Country (2018-2023)

Table 53. Middle East & Africa Recombinant Human GM-CSF for Injection Revenue by Country (2018-2023) & (\$ Millions)

Table 54. Middle East & Africa Recombinant Human GM-CSF for Injection Revenue Market Share by Country (2018-2023)

Table 55. Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Type (2018-2023) & (K Units)

Table 56. Middle East & Africa Recombinant Human GM-CSF for Injection Sales by Application (2018-2023) & (K Units)

Table 57. Key Market Drivers & Growth Opportunities of Recombinant Human GM-CSF for Injection

Table 58. Key Market Challenges & Risks of Recombinant Human GM-CSF for Injection

Table 59. Key Industry Trends of Recombinant Human GM-CSF for Injection

Table 60. Recombinant Human GM-CSF for Injection Raw Material

Table 61. Key Suppliers of Raw Materials

- Table 62. Recombinant Human GM-CSF for Injection Distributors List
- Table 63. Recombinant Human GM-CSF for Injection Customer List
- Table 64. Global Recombinant Human GM-CSF for Injection Sales Forecast by Region (2024-2029) & (K Units)
- Table 65. Global Recombinant Human GM-CSF for Injection Revenue Forecast by Region (2024-2029) & (\$ millions)
- Table 66. Americas Recombinant Human GM-CSF for Injection Sales Forecast by Country (2024-2029) & (K Units)
- Table 67. Americas Recombinant Human GM-CSF for Injection Revenue Forecast by Country (2024-2029) & (\$ millions)
- Table 68. APAC Recombinant Human GM-CSF for Injection Sales Forecast by Region (2024-2029) & (K Units)
- Table 69. APAC Recombinant Human GM-CSF for Injection Revenue Forecast by Region (2024-2029) & (\$ millions)
- Table 70. Europe Recombinant Human GM-CSF for Injection Sales Forecast by Country (2024-2029) & (K Units)
- Table 71. Europe Recombinant Human GM-CSF for Injection Revenue Forecast by Country (2024-2029) & (\$ millions)
- Table 72. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Forecast by Country (2024-2029) & (K Units)
- Table 73. Middle East & Africa Recombinant Human GM-CSF for Injection Revenue Forecast by Country (2024-2029) & (\$ millions)
- Table 74. Global Recombinant Human GM-CSF for Injection Sales Forecast by Type (2024-2029) & (K Units)
- Table 75. Global Recombinant Human GM-CSF for Injection Revenue Forecast by Type (2024-2029) & (\$ Millions)
- Table 76. Global Recombinant Human GM-CSF for Injection Sales Forecast by Application (2024-2029) & (K Units)
- Table 77. Global Recombinant Human GM-CSF for Injection Revenue Forecast by Application (2024-2029) & (\$ Millions)
- Table 78. Sanofi Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors
- Table 79. Sanofi Recombinant Human GM-CSF for Injection Product Portfolios and Specifications
- Table 80. Sanofi Recombinant Human GM-CSF for Injection Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 81. Sanofi Main Business
- Table 82. Sanofi Latest Developments
- Table 83. Changchun GeneScience Basic Information, Recombinant Human GM-CSF

for Injection Manufacturing Base, Sales Area and Its Competitors

Table 84. Changchun GeneScience Recombinant Human GM-CSF for Injection Product Portfolios and Specifications

Table 85. Changchun GeneScience Recombinant Human GM-CSF for Injection Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 86. Changchun GeneScience Main Business

Table 87. Changchun GeneScience Latest Developments

Table 88. Hainan Unipul Pharmaceutical Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors

Table 89. Hainan Unipul Pharmaceutical Recombinant Human GM-CSF for Injection Product Portfolios and Specifications

Table 90. Hainan Unipul Pharmaceutical Recombinant Human GM-CSF for Injection Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 91. Hainan Unipul Pharmaceutical Main Business

Table 92. Hainan Unipul Pharmaceutical Latest Developments

Table 93. Harbin Pharmaceutical Group Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors

Table 94. Harbin Pharmaceutical Group Recombinant Human GM-CSF for Injection Product Portfolios and Specifications

Table 95. Harbin Pharmaceutical Group Recombinant Human GM-CSF for Injection Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 96. Harbin Pharmaceutical Group Main Business

Table 97. Harbin Pharmaceutical Group Latest Developments

Table 98. Guangzhou Baiyunshan Baidi Biotechnology Basic Information, Recombinant Human GM-CSF for Injection Manufacturing Base, Sales Area and Its Competitors

Table 99. Guangzhou Baiyunshan Baidi Biotechnology Recombinant Human GM-CSF for Injection Product Portfolios and Specifications

Table 100. Guangzhou Baiyunshan Baidi Biotechnology Recombinant Human GM-CSF for Injection Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 101. Guangzhou Baiyunshan Baidi Biotechnology Main Business

Table 102. Guangzhou Baiyunshan Baidi Biotechnology Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Recombinant Human GM-CSF for Injection

Figure 2. Recombinant Human GM-CSF for Injection Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Recombinant Human GM-CSF for Injection Sales Growth Rate 2018-2029 (K Units)

Figure 7. Global Recombinant Human GM-CSF for Injection Revenue Growth Rate 2018-2029 (\$ Millions)

Figure 8. Recombinant Human GM-CSF for Injection Sales by Region (2018, 2022 & 2029) & (\$ Millions)

Figure 9. Product Picture of 75ug

Figure 10. Product Picture of 150ug

Figure 11. Global Recombinant Human GM-CSF for Injection Sales Market Share by Type in 2022

Figure 12. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Type (2018-2023)

Figure 13. Recombinant Human GM-CSF for Injection Consumed in Hospital

Figure 14. Global Recombinant Human GM-CSF for Injection Market: Hospital (2018-2023) & (K Units)

Figure 15. Recombinant Human GM-CSF for Injection Consumed in Clinic

Figure 16. Global Recombinant Human GM-CSF for Injection Market: Clinic (2018-2023) & (K Units)

Figure 17. Recombinant Human GM-CSF for Injection Consumed in Others

Figure 18. Global Recombinant Human GM-CSF for Injection Market: Others (2018-2023) & (K Units)

Figure 19. Global Recombinant Human GM-CSF for Injection Sales Market Share by Application (2022)

Figure 20. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Application in 2022

Figure 21. Recombinant Human GM-CSF for Injection Sales Market by Company in 2022 (K Units)

Figure 22. Global Recombinant Human GM-CSF for Injection Sales Market Share by Company in 2022

Figure 23. Recombinant Human GM-CSF for Injection Revenue Market by Company in

2022 (\$ Million)

Figure 24. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Company in 2022

Figure 25. Global Recombinant Human GM-CSF for Injection Sales Market Share by Geographic Region (2018-2023)

Figure 26. Global Recombinant Human GM-CSF for Injection Revenue Market Share by Geographic Region in 2022

Figure 27. Americas Recombinant Human GM-CSF for Injection Sales 2018-2023 (K Units)

Figure 28. Americas Recombinant Human GM-CSF for Injection Revenue 2018-2023 (\$ Millions)

Figure 29. APAC Recombinant Human GM-CSF for Injection Sales 2018-2023 (K Units)

Figure 30. APAC Recombinant Human GM-CSF for Injection Revenue 2018-2023 (\$ Millions)

Figure 31. Europe Recombinant Human GM-CSF for Injection Sales 2018-2023 (K Units)

Figure 32. Europe Recombinant Human GM-CSF for Injection Revenue 2018-2023 (\$ Millions)

Figure 33. Middle East & Africa Recombinant Human GM-CSF for Injection Sales 2018-2023 (K Units)

Figure 34. Middle East & Africa Recombinant Human GM-CSF for Injection Revenue 2018-2023 (\$ Millions)

Figure 35. Americas Recombinant Human GM-CSF for Injection Sales Market Share by Country in 2022

Figure 36. Americas Recombinant Human GM-CSF for Injection Revenue Market Share by Country in 2022

Figure 37. Americas Recombinant Human GM-CSF for Injection Sales Market Share by Type (2018-2023)

Figure 38. Americas Recombinant Human GM-CSF for Injection Sales Market Share by Application (2018-2023)

Figure 39. United States Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 (\$ Millions)

Figure 40. Canada Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 (\$ Millions)

Figure 41. Mexico Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 (\$ Millions)

Figure 42. Brazil Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 (\$ Millions)

Figure 43. APAC Recombinant Human GM-CSF for Injection Sales Market Share by

Region in 2022

Figure 44. APAC Recombinant Human GM-CSF for Injection Revenue Market Share by Regions in 2022

Figure 45. APAC Recombinant Human GM-CSF for Injection Sales Market Share by Type (2018-2023)

Figure 46. APAC Recombinant Human GM-CSF for Injection Sales Market Share by Application (2018-2023)

Figure 47. China Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 (\$ Millions)

Figure 48. Japan Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 (\$ Millions)

Figure 49. South Korea Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 (\$ Millions)

Figure 50. Southeast Asia Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 (\$ Millions)

Figure 51. India Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 (\$ Millions)

Figure 52. Australia Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 (\$ Millions)

Figure 53. China Taiwan Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 (\$ Millions)

Figure 54. Europe Recombinant Human GM-CSF for Injection Sales Market Share by Country in 2022

Figure 55. Europe Recombinant Human GM-CSF for Injection Revenue Market Share by Country in 2022

Figure 56. Europe Recombinant Human GM-CSF for Injection Sales Market Share by Type (2018-2023)

Figure 57. Europe Recombinant Human GM-CSF for Injection Sales Market Share by Application (2018-2023)

Figure 58. Germany Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 (\$ Millions)

Figure 59. France Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 (\$ Millions)

Figure 60. UK Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 (\$ Millions)

Figure 61. Italy Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 (\$ Millions)

Figure 62. Russia Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 (\$ Millions)

Figure 63. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Market Share by Country in 2022

Figure 64. Middle East & Africa Recombinant Human GM-CSF for Injection Revenue Market Share by Country in 2022

Figure 65. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Market Share by Type (2018-2023)

Figure 66. Middle East & Africa Recombinant Human GM-CSF for Injection Sales Market Share by Application (2018-2023)

Figure 67. Egypt Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 (\$ Millions)

Figure 68. South Africa Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 (\$ Millions)

Figure 69. Israel Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 (\$ Millions)

Figure 70. Turkey Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 (\$ Millions)

Figure 71. GCC Country Recombinant Human GM-CSF for Injection Revenue Growth 2018-2023 (\$ Millions)

Figure 72. Manufacturing Cost Structure Analysis of Recombinant Human GM-CSF for Injection in 2022

Figure 73. Manufacturing Process Analysis of Recombinant Human GM-CSF for Injection

Figure 74. Industry Chain Structure of Recombinant Human GM-CSF for Injection

Figure 75. Channels of Distribution

Figure 76. Global Recombinant Human GM-CSF for Injection Sales Market Forecast by Region (2024-2029)

Figure 77. Global Recombinant Human GM-CSF for Injection Revenue Market Share Forecast by Region (2024-2029)

Figure 78. Global Recombinant Human GM-CSF for Injection Sales Market Share Forecast by Type (2024-2029)

Figure 79. Global Recombinant Human GM-CSF for Injection Revenue Market Share Forecast by Type (2024-2029)

Figure 80. Global Recombinant Human GM-CSF for Injection Sales Market Share Forecast by Application (2024-2029)

Figure 81. Global Recombinant Human GM-CSF for Injection Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Recombinant Human GM-CSF for Injection Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/GC9A1E7871CEEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC9A1E7871CEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970